Yea Christopher 4

What Happened

• Christopher Yea, Chief Development Officer at KalVista Pharmaceuticals (KALV), had 1,774 restricted stock units (RSUs) vest and convert into shares on Feb 17, 2026 (settled for no cash). Following that settlement, he sold 1,109 shares in an open-market transaction on Feb 18, 2026 at $15.00 per share, generating $16,635. The sale was a sell-to-cover to satisfy tax withholding related to the RSU settlement.

Key Details

• Transaction dates: RSU settlement (conversion) on 2026-02-17; open-market sale on 2026-02-18.
• Sale details: 1,109 shares sold at $15.00 each — total proceeds $16,635.
• RSU settlement: 1,774 RSUs converted to shares on 2026-02-17 (settled for no consideration).
• Resulting shares from this grant: 1,774 settled − 1,109 sold = 665 shares retained from this settlement (prior overall holdings not shown).
• Footnotes: F1 = each RSU converts to 1 share upon settlement for no consideration; F2 = sale was to cover tax withholding (sell-to-cover), not a discretionary trade; F3 = RSUs vest 1/16th quarterly from the vesting start date.
• Filing timeliness: Form 4 filed 2026-02-19 reporting the Feb 17–18 transactions — filed within the typical Form 4 reporting window (timely).

Context

• This was not a purchase signal; it was a routine sell-to-cover following RSU vesting. For derivative/award activity, the important points are that the RSUs vested (converted to shares) and a portion was immediately sold to cover taxes. Such sell-to-cover transactions are common and generally reflect tax obligations rather than a change in insider sentiment.